The cloud-based platform enhances
FibroScan® capabilities, providing advanced tools for
data-driven liver disease management
PARIS, Nov. 4, 2024
/PRNewswire/ -- Liver disease affects an estimated 1.5 billion
people worldwide, with many cases going undiagnosed until it's too
late. As liver conditions like metabolic dysfunction-associated
steatotic liver disease (MASLD) and metabolic
dysfunction-associated steatohepatitis (MASH) become more common,
the need for early detection and proactive management has never
been more urgent. To address this global health crisis, Echosens
has launched its Liver Health Management (LHM) platform—a
cloud-based solution designed to streamline liver disease care for
healthcare providers in diverse clinical environments.
The LHM platform integrates seamlessly with Echosens'
FibroScan® technology, offering automated result
transfers, biological marker-enhanced exams, and interpretation
tools that support more informed, data-driven decision-making.
"The LHM platform is designed to meet the growing needs of
healthcare providers who are seeing an increase in patients with
liver disease," said Dominique
Legros, Group CEO of Echosens. "By connecting
FibroScan® with the LHM platform, providers can access
real-time insights and deliver more precise, data-driven care. The
platform unlocks next-level liver disease management, enhancing
efficiency and empowering clinicians to streamline workflows,
improve patient outcomes, and stay ahead of the rising demand for
liver care."
Key features of the LHM platform, including worklist
synchronization between FibroScan® devices and the
platform, remote results interpretation, and secure data storage,
allow providers to easily integrate liver care into their clinical
workflows. This ensures efficient management of patient data while
delivering comprehensive liver assessments.
"The LHM platform is transforming our ability to monitor and
manage liver disease," said gastroenterologist, Dr. Angelo Paredes. "With automated
FibroScan® result transfers and intuitive interpretation
tools, we can quickly identify at-risk patients and make informed
decisions, allowing us to deliver timely recommendations and
interventions to improve patient outcomes."
Liver disease often progresses silently, with symptoms appearing
only in advanced stages. With one in four people affected by MASLD
and many undiagnosed, the LHM platform provides a critical solution
by making liver screening routine, accessible, and actionable.
"With the increasing prevalence of MASLD and MASH, the LHM
platform provides essential support for clinicians seeking to catch
the disease early, while it's still reversible," added Legros. "Our
goal is to empower clinicians to intervene sooner, giving patients
the best chance to improve their liver health, especially as
more targeted treatments become available, such as Rezdiffra™,
launched by Madrigal Pharmaceuticals earlier this year."
For more information or to integrate the LHM platform into your
practice, visit https://www.echosens.com/en-us/lhm/.
About Echosens
A pioneer in liver health, Echosens
revolutionized liver diagnostics with FibroScan®, a
non-invasive solution for comprehensive liver assessment. Validated
by over 4,200 peer-reviewed publications and featured in 180+
international guidelines, FibroScan® is available in
more than 127 countries, enabling millions of liver examinations
worldwide. https://www.echosens.com/.
Logo -
https://mma.prnewswire.com/media/2370966/Logo_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/echosens-launches-its-liver-health-management-lhm-platform-globally-streamlining-liver-care-302290884.html